Pheochromocytoma: Current approaches and future directions

Oncologist

Volumn 13, Issue 7, 2008, Pages 779-793

  Adler, Joel T ^a   Meyer Rochow, Goswin Y ^b,c   Chen, Herbert ^a   Benn, Diana E ^c   Robinson, Bruce G ^b,c   Sippel, Rebecca S ^a,d   Sidhu, Stan B ^b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d University of Wisconsin Health   (United States)

Author keywords

Adrenal gland; Familial pheochromocytoma; Management; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ADRENALIN; AMLODIPINE; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DOXAZOSIN; FLUORODEOXYGLUCOSE F 18; FLUORODOPAMINE F 18; GLYCERYL TRINITRATE; HYDROXYEPHEDRINE C 11; LABETALOL; MAGNESIUM SULFATE; METIROSINE; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHENOXYBENZAMINE; PHENTOLAMINE; PRAZOSIN; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; SODIUM CHLORIDE; TERAZOSIN; UNINDEXED DRUG; URAPIDIL; VERAPAMIL;

ADRENAL INCIDENTALOMA; ADRENALECTOMY; ADRENALIN RELEASE; AUTOSOMAL DOMINANT INHERITANCE; BENIGN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL FEATURE; COLLOID; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; ECTOPIC HORMONE PRODUCTION; FLUID THERAPY; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; GERM LINE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; LAPAROSCOPIC SURGERY; NEUROFIBROMATOSIS; NORADRENALIN RELEASE; PARAGANGLIOMA SYNDROME; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RADIODIAGNOSIS; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SIPPLE SYNDROME; SURGICAL APPROACH; TREATMENT OUTCOME; TUMOR DIAGNOSIS; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; CHEMOTHERAPY, ADJUVANT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASM METASTASIS; PHEOCHROMOCYTOMA; RADIOTHERAPY, ADJUVANT;

EID: 48749092390     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0043     Document Type: Review

References (166)

1. Fränkel F. Ein Fall von doppelseitigem, völlig latent verlaufenen Nebennierentumor und gleichzeitiger Nephritis mit Veränderungen am Circulationsapparat und Retinitis. Arch Pathol Anat Physiol Klin Med 1886;103:244-263.
2. Classics in oncology. A case of bilateral completely latent adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis: Felix Frankel, 1886. CA Cancer J Clin 1984;34:93-106.
3. Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience. Medicine (Baltimore) 1991;70:46-66.
4. Mantero F, Terzolo M, Arnaldi G et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85:637-644.
5. Sidhu S, Bambach C, Pillinger S et al. Changing pattern of adrenalectomy at a tertiary referral centre 1970-2000. ANZ J Surg 2002;72:463-466.
6. Bravo EL, Gifford RW Jr. Current concepts. Pheochromocytoma: Diagnosis, localization and management. N Engl J Med 1984;311:1298-1303.
7. Dluhy RG. Pheochromocytoma - death of an axiom. N Engl J Med 2002;346:1486-1488.
8. Neumann HP, Bausch B, McWhinney SR et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459-1466.
9. Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005;90:2110-2116.
10. Manger WM. The vagaries of pheochromocytomas. Am J Hypertens 2005;18:1266-1270.
11. Manger WM, Gifford JRW. Clinical and Experimental Pheochromocytoma. Cambridge, MA: Blackwell Science, 1996:1-570.
12. Baguet JP, Hammer L, Mazzuco TL et al. Circumstances of discovery of phaeochromocytoma: A retrospective study of 41 consecutive patients. Eur J Endocrinol 2004;150:681-686.
13. Pacak K, Linehan WM, Eisenhofer G et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:315-329.
14. Alderazi Y, Yeh MW, Robinson BG et al. Phaeochromocytoma: Current concepts. Med J Aust 2005;183:201-204.
15. Manger WM. An overview of pheochromocytoma: History, current concepts, vagaries, and diagnostic challenges. Ann N Y Acad Sci 2006;1073:1-20.
16. Young WF Jr, Maddox DE. Spells: In search of a cause. Mayo Clin Proc 1995;70:757-765.
17. Mannelli M, Ianni L, Cilotti A et al. Pheochromocytoma in Italy: A multicentric retrospective study. Eur J Endocrinol 1999;141:619-624.
18. Zelinka T, Widimsky J, Weisserova J. Diminished circadian blood pressure rhythm in patients with asymptomatic normotensive pheochromocytoma. Physiol Res 2001;50:631-634.
19. Herrera MF, Grant CS, van Heerden JA et al. Incidentally discovered adrenal tumors: An institutional perspective. Surgery 1991;110:1014-1021.
20. Hedeland H, Ostberg G, Hökfelt B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand 1968;184:211-214.
21. Bouloux PG, Fakeeh M. Investigation of phaeochromocytoma. Clin Endocrinol (Oxf) 1995;43:657-664.
22. Kloos RT, Gross MD, Francis IR et al. Incidentally discovered adrenal masses. Endocr Rev 1995;16:460-484.
23. Weismann D, Fassnacht M, Schubert B et al. A dangerous liaison - pheochromocytoma in patients with malignant disease. Ann Surg Oncol 2006;13:1696-1701.
24. Lenert JT, Barnett CC Jr, Kudelka AP et al. Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. Surgery 2001;130:1060-1067.
25. Adler JT, Mack E, Chen H. Isolated adrenal mass in patients with a history of cancer: Remember pheochromocytoma. Ann Surg Oncol 2007;14:2358-2362.
26. Grumbach MM, Biller BM, Braunstein GD et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 2003;138:424-429.
27. Mitchell IC, Nwariaku FE. Adrenal masses in the cancer patient: Surveillance or excision. The Oncologist 2007;12:168-174.
28. Amar L, Bertherat J, Baudin E et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005;23:8812-8818.
29. Astuti D, Latif F, Dallol A et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001;69:49-54.
30. Niemann S, Ml̈ler U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000;26:268-270.
31. Baysal BE, Ferrell RE, Willett-Brozick JE et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848-851.
32. Mannelli M, Simi L, Gagliano MS et al. Genetics and biology of pheochromocytoma. Exp Clin Endocrinol Diabetes 2007;115:160-165.
33. Walther MM, Keiser HR, Linehan WM. Pheochromocytoma: Evaluation, diagnosis, and treatment. World J Urol 1999;17:35-39.
34. Lenders JW, Eisenhofer G, Mannelli M et al. Phaeochromocytoma. Lancet 2005;366:665-675.
35. Maher ER, Yates JR, Harries R et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-1163.
36. Friedrich CA. von Hippel-Lindau syndrome. A pleomorphic condition. Cancer 1999;86(11 suppl):2478-2482.
37. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-391.
38. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995;273:564-570.
39. Filling-Katz MR, Choyke PL, Oldfield E et al. Central nervous system involvement in von Hippel-Lindau disease. Neurology 1991;41:41-46.
40. Choyke PL, Glenn GM, Walther MM et al. von Hippel-Lindau disease: Genetic, clinical, and imaging features. Radiology 1995;194:629-642.
41. Walther MM, Reiter R, Keiser HR et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: Comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 1999;162:659-664.
42. Lonser RR, Glenn GM, Walther M et al. von Hippel-Lindau disease. Lancet 2003;361:2059-2067.
43. Brauch H, Hoeppner W, Jahnig H et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. J Clin Endocrinol Metab 1997;82:4101-4104.
44. van der Harst E, de Krijger RR, Dinjens WN et al. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer 1998;77:337-340.
45. Eisenhofer G, Walther MM, Huynh TT et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001;86:1999-2008.
46. Easton DF, Ponder MA, Cummings T et al. The clinical and screening age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet 1989;44:208-215.
47. Ponder BA, Ponder MA, Coffey R et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988;1:397-401.
48. Gagel RF, Tashjian AH Jr, Cummings T et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988;318:478-484.
49. Modigliani E, Vasen HM, Raue K et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med 1995;238:363-367.
50. Bryant J, Farmer J, Kessler LJ et al. Pheochromocytoma: The expanding genetic differential diagnosis. J Natl Cancer Inst 2003;95:1196-1204.
51. Plouin PF, Gimenez-Roqueplo AP. The genetic basis of pheochromocytoma: Who to screen and how? Nat Clin Pract Endocrinol Metab 2006;2:60-61.
52. Cantor AM, Rigby CC, Beck PR et al. Neurofibromatosis, phaeochromocytoma, and somatostatinoma. Br Med J (Clin Res Ed) 1982;285:1618-1619.
53. Zhu Y, Parada LF. Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res 2001;264:19-28.
54. Machens A, Brauckhoff M, Gimm O et al. Risk-oriented approach to hereditary adrenal pheochromocytoma. Ann N Y Acad Sci 2006;1073:417-428.
55. Gimenez-Roqueplo AP, Lehnert H, Mannelli M et al. Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 2006;65:699-705.
56. Brouwers FM, Eisenhofer G, Tao JJ et al. High frequency of SDHB germ-line mutations in patients with malignant catecholamine-producing paragangliomas: Implications for genetic testing. J Clin Endocrinol Metab 2006;91:4505-4509.
57. Benn DE, Gimenez-Roqueplo AP, Reilly JR et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006;91:827-836.
58. Mannelli M, Ercolino T, Giache V et al. Genetic screening for pheochromocytoma: Should SDHC gene analysis be included? J Med Genet 2007;44:586-587.
59. Neumann HP, Pawlu C, Peczkowska M et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004;292:943-951.
60. Martin TP, Irving RM, Maher ER. The genetics of paragangliomas: A review. Clin Otolaryngol 2007;32:7-11.
61. Benn DE, Richardson AL, Marsh DJ et al. Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes. Ann N Y Acad Sci 2006;1073:104-111.
62. Arnaldi G, Masini AM, Giacchetti G et al. Adrenal incidentaloma. Braz J Med Biol Res 2000;33:1177-1189.
63. Kudva YC, Sawka AM, Young WF Jr. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: The Mayo Clinic experience. J Clin Endocrinol Metab 2003;88:4533-4539.
64. Sawka AM, Jaeschke R, Singh RJ et al. A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003;88:553-558.
65. Smythe GA, Edwards G, Graham P et al. Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine. Clin Chem 1992;38:486-492.
66. Harding JL, Yeh MW, Robinson BG et al. Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust 2005;182:637-640.
67. Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: Which test is best? JAMA 2002;287:1427-1434.
68. Sawka AM, Prebtani AP, Thabane L et al. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord 2004;4:2.
69. Eisenhofer G, Goldstein DS, Walther MM et al. Biochemical diagnosis of pheochromocytoma: How to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003;88:2656-2666.
70. Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 1992;152:1193-1197.
71. Elliott WJ, Murphy MB. Reduced specificity of the clonidine suppression test in patients with normal plasma catecholamine levels. Am J Med 1988;84:419-424.
72. Lawrence AM. Glucagon and pheochromocytoma. Ann Intern Med 1970;73:852-853.
73. Lawrence AM. Glucagon provocative test for pheochromocytoma. Ann Intern Med 1967;66:1091-1096.
74. Apgar V, Papper EM. Pheochromocytoma. Anesthetic management during surgical treatment. AMA Arch Surg 1951;62:634-648.
75. Plouin PF, Duclos JM, Soppelsa F et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: Analysis of 165 operations at a single center. J Clin Endocrinol Metab 2001;86:1480-1486.
76. Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002;16:359-369.
77. Shulkin BL, Ilias I, Sisson JC et al. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006;1073:374-382.
78. Bravo EL. Pheochromocytoma: New concepts and future trends. Kidney Int 1991;40:544-556.
79. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994;15:356-368.
80. Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999;229:755-764; discussion 764-766.
81. Maurea S, Cuocolo A, Reynolds JC et al. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med 1996;40:365-371.
82. Lumachi F, Tregnaghi A, Zucchetta P et al. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: A prospective study. Nucl Med Commun 2006;27:583-587.
83. Maurea S, Cuocolo A, Reynolds JC et al. Iodine-131-metaiodobenzyl- guanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: Comparison with CT and MRI. J Nucl Med 1993;34:173-179.
84. Lebuffe G, Dosseh ED, Tek G et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 2005;60:439-444.
85. Takahashi S, Nakai T, Fujiwara R et al. Effectiveness of long-acting nifedipine in pheochromocytoma. Jpn Heart J 1989;30:751-757.
86. Van Der Horst-Schrivers AN, Jager PL, Boezen HM et al. Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas - experience and meta-analysis. Anticancer Res 2006;26:1599-1604.
87. Ilias I, Yu J, Carrasquillo JA et al. Superiority of 6-[18F]- fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003;88:4083-4087.
88. Fujita A, Hyodoh H, Kawamura Y et al. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med 2000;25:440-442.
89. Shapiro B. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: A personal overview and concluding remarks. Q J Nucl Med 1995;39(suppl 1):150-155.
90. Shulkin BL, Thompson NW, Shapiro B et al. Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999;212:35-41.
91. Neumann DR, Basile KE, Bravo EL et al. Malignant pheochromocytoma of the anterior mediastinum: PET findings with [18F]FDG and 82Rb. J Comput Assist Tomogr 1996;20:312-316.
92. Shulkin BL, Wieland DM, Schwaiger M et al. PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J Nucl Med 1992;33:1125-1131.
93. Timmers HJ, Kozupa A, Chen CC et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007;25:2262-2269.
94. Esfandiari NH, Shulkin BL, Bui C et al. Multimodality imaging of malignant pheochromocytoma. Clin Nucl Med 2006;31:822-825.
95. Bravo EL, Tagle R. Pheochromocytoma: State-of-the-art and future prospects. Endocr Rev 2003;24:539-553.
96. Schütler J, Westhofen P, Kania U et al. [Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. Anasthesiol Intensivmed Notfallmed Schmerzther 1995;30:341-349. German.
97. Khorram-Manesh A, Ahlman H, Nilsson O et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med 2005;258:55-66.
98. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma - views on current management. Eur J Surg Oncol 2003;29:483-490.
99. Russell WJ, Metcalfe IR, Tonkin AL et al. The preoperative management of phaeochromocytoma. Anaesth Intensive Care 1998;26:196-200.
100. Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006;1073:405-416.
101. Bravo EL. Pheochromocytoma: An approach to antihypertensive management. Ann N Y Acad Sci 2002;970:1-10.
102. Prys-Roberts C. Phaeochromocytoma - recent progress in its management. Br J Anaesth 2000;85:44-57.
103. Steinsapir J, Carr AA, Prisant LM et al. Metyrosine and pheochromocytoma. Arch Intern Med 1997;157:901-906.
104. Kanto JH. Current status of labetalol, the first alpha- and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol 1985;23:617-628.
105. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007;92:4069-4079.
106. Sugano O, Hirano J, Hirano K et al. [Malignant pheochromocytoma: Blood pressure controlled by labetalol]. Nippon Hinyokika Gakkai Zasshi 1984;75:523-527. Japanese.
107. Rosei EA, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol. Br J Clin Pharmacol 1976;3(suppl 3):809-815.
108. Elliott HL, Meredith PA, Vincent J et al. Clinical pharmacological studies with doxazosin. Br J Clin Pharmacol 1986;21(suppl 1):27S-31S.
109. Bravo EL. Pheochromocytoma. Curr Ther Endocrinol Metab 1997;6:195-197.
110. Lehmann HU, Hochrein H, Witt E et al. Hemodynamic effects of calcium antagonists. Review. Hypertension 1983;5:II66-II73.
111. Proye C, Thevenin D, Cecat P et al. Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: Hemodynamics and free catecholamine assays in ten consecutive patients. Surgery 1989;106:1149-1154.
112. Engelman K, Horwitz D, Jéquier E et al. Biochemical and pharmacologic effects of alpha-methyltyrosine in man. J Clin Invest 1968;47:577-594.
113. Brogden RN, Heel RC, Speight TM et al. α-methyl-p-tyrosine: A review of its pharmacology and clinical use. Drugs 1981;21:81-89.
114. Hengstmann JH, Gugler R, Dengler HJ. Malignant pheochromocytoma. Effect of oral alpha-methyl-p-tyrosine upon catecholamine metabolism. Klin Wochenschr 1979;57:351-355.
115. Gumbs AA, Gagner M. Laparoscopic adrenalectomy. Best Pract Res Clin Endocrinol Metab 2006;20:483-499.
116. Shen WT, Sturgeon C, Clark OH et al. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 2004;136:1129-1137.
117. Ippolito G, Palazzo FF, Sebag F et al. Safety of laparoscopic adrenalectomy in patients with large pheochromocytomas: A single institution review. World J Surg 2008;32:840-844; discussion 845-846.
118. Soon PS, Yeh MW, Delbridge LW et al. Laparoscopic surgery is safe for large adrenal lesions. Eur J Surg Oncol 2008;34:67-70.
119. van Heerden JA, Roland CF, Carney JA et al. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). World J Surg 1990;14:325-329.
120. Solorzano CC, Lew JI, Wilhelm SM et al. Outcomes of pheochromocytoma management in the laparoscopic era. Ann Surg Oncol 2007;14:3004-3010.
121. Dimas S, Roukounakis N, Kafetzis I et al. Feasibility of laparoscopic adrenalectomy for large pheochromocytomas. JSLS 2007;11:30-33.
122. Lee JE, Curley SA, Gagel RF et al. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996;120:1064-1070; discussion 1070-1071.
123. Jansson S, Khorram-Manesh A, Nilsson O et al. Treatment of bilateral pheochromocytoma and adrenal medullary hyperplasia. Ann N Y Acad Sci 2006;1073:429-435.
124. Yip L, Lee JE, Shapiro SE et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 2004;198:525-534; discussion 534-535.
125. Snavely MD, Mahan LC, O'Connor DT et al. Selective down-regulation of adrenergic receptor subtypes in tissues from rats with pheochromocytoma. Endocrinology 1983;113:354-361.
126. Meeke RI, O'Keeffe JD, Gaffney JD. Phaeochromocytoma removal and postoperative hypoglycaemia. Anaesthesia 1985;40:1093-1096.
127. Plouin PF, Chatellier G, Fofol I, et al. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997;29:1133-1139.
128. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. WHO Classification of Tumours - Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004:147-150.
129. Pattarino F, Bouloux PM. The diagnosis of malignancy in phaeochromocytoma. Clin Endocrinol (Oxf) 1996;44:239-241.
130. Brouwers FM, Petricoin EF 3rd, Ksinantova L et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 2005;12:263-272.
131. Chrisoulidou A, Kaltsas G, Ilias I et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569-585.
132. Helman LJ, Cohen PS, Averbuch SD et al. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 1989;7:1720-1725.
133. Gimenez-Roqueplo AP, Favier J, Rustin P et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003;63:5615-5621.
134. Nativ O, Grant CS, Sheps SG et al. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer 1992;69:2683-2687.
135. Brouwers FM, Elkahloun AG, Munson PJ et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci 2006;1073:541-556.
136. Thouennon E, Elkahloun AG, Guillemot J et al. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab 2007;92:4865-4872.
137. O'Riordain DS, Young WF Jr, Grant CS et al. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 1996;20:916-921; discussion 922.
138. John H, Ziegler WH, Hauri D et al. Pheochromocytomas: Can malignant potential be predicted? Urology 1999;53:679-683.
139. Manger WM, Eisenhofer G. Pheochromocytoma: Diagnosis and management update. Curr Hypertens Rep 2004;6:477-484.
140. Sisson JC, Shulkin BL, Esfandiari NH. Courses of malignant pheochromocytoma: Implications for therapy. Ann N Y Acad Sci 2006;1073:505-511.
141. Eisenhofer G, Bornstein SR, Brouwers FM et al. Malignant pheochromocytoma: Current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423-436.
142. Eisenhofer G, Lenders JW, Pacak K. Biochemical diagnosis of pheochromocytoma. Front Horm Res 2004;31:76-106.
143. Kebebew E, Duh QY. Benign and malignant pheochromocytoma: Diagnosis, treatment, and follow-up. Surg Oncol Clin N Am 1998;7:765-789.
144. Pacak K, Fojo T, Goldstein DS et al. Radiofrequency ablation: A novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst 2001;93:648-649.
145. Takahashi K, Ashizawa N, Minami T et al. Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Intern Med 1999;38:349-354.
146. 131IMIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648-658.
147. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001;12:469-475.
148. Kaltsas GA, Papadogias D, Makras P et al. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005;12:683-699.
149. Averbuch SD, Steakley CS, Young RC et al. Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988;109:267-273.
150. Scholz T, Eisenhofer G, Pacak K et al. Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007;92:1217-1225.
151. Schlumberger M, Gicquel C, Lumbroso J et al. Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992;15:631-642.
152. Nakane M, Takahashi S, Sekine I et al. Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol 2003;14:1449-1451.
153. Iwabuchi M, Oki Y, Nakamura H. Palliative chemotherapy for malignant pheochromocytoma: Symptomatic palliation of two cases. Intern Med 1999;38:433-435.
154. Kulke MH, Stuart K, Enzinger PC et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406.
155. Gross DJ, Munter G, Bitan M et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-Kit or PDGF-R. Endocr Relat Cancer 2006;13:535-540.
156. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377-383.
157. Bornstein SR, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma: Increasing importance for clinical decision making. Ann N Y Acad Sci 2006;1073:94-103.
158. Favier J, Briere JJ, Strompf L et al. Hereditary paraganglioma/ pheochromocytoma and inherited succinate dehydrogenase deficiency. Horm Res 2005;63:171-179.
159. Dahia PL. Evolving concepts in pheochromocytoma and paraganglioma. Curr Opin Oncol 2006;18:1-8.
160. Sisson JC, Shapiro B, Shulkin BL et al. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol 1999;22:364-370.
161. Kappes A, Vaccaro A, Kunnimalaiyaan M et al. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. J Surg Res 2006;133:42-45.
162. Kappes A, Vaccaro A, Kunnimalaiyaan M et al. Lithium ions: A novel treatment for pheochromocytomas and paragangliomas. Surgery 2007;141:161-165; discussion 165.
163. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Histone deacetylase inhibitors upregulate notch1 and inhibit growth in pheochromocytoma cells. Surgery 2008 (in press).
164. Maher ER, Eng C. The pressure rises: Update on the genetics of phaeochromocytoma. Hum Mol Genet 2002;11:2347-2354.
165. Schiavi F, Boedeker CC, Bausch B et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 2005;294:2057-2063.
166. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002;26:551-566.